Vieitez, Irene
Souto-Rodriguez, Olga
Fernandez-Mosquera, Lorena
San Millan, Beatriz
Teijeira, Susana
Fernandez-Martin, Julian
Martinez-Sanchez, Felisa
Aldamiz-Echevarria, Luis Jose
Lopez-Rodriguez, Monica
Navarro, Carmen
Ortolano, Saida http://orcid.org/0000-0002-1098-3376
Funding for this research was provided by:
Instituto de Salud Carlos III (PI11-00842)
Shire Ibérica Human Genetic Therapies
Article History
Received: 8 November 2017
Accepted: 22 March 2018
First Online: 10 April 2018
Ethics approval and consent to participate
: The study was approved by the Galician Clinical Research Ethics Committee (Ref 2009/182, up-date on March 29th 2011). All patients involved in the study signed the informed consent.
: Not applicable.
: SO, CN were principal investigators in projects sponsored by the pharmaceutical company Shire Ibérica Human Genetic Therapies. SO, CN, BS, JFM, LJAE, MLR and FMS, have also been invited to attend or give conferences by Shire Ibérica Human Genetic Therapies and or Sanofi-Genzyme.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.